Classification of integrable discrete Klein-Gordon models

The Lie algebraic integrability test is applied to the problem of classification of integrable Klein-Gordon type equations on quad-graphs. The list of equations passing the test is presented containing several well-known integrable models. A new integrable example is found, its higher symmetry is presented.Comment: 12 pages, submitted to Physica Script

The role of small intestine in pathogenesis of common variable immune deficiency

The article presents the results of examination of 32 patients with common variable immune deficiency (barn) with involvement in the pathological process of the digestive system. The features of the clinical picture, the content of immunoglobulins in the blood serum, morphological structure of the mucosa of small intestine as well as treatment. Special attention is paid to the small intestine in the pathogenesis of the barn

Sub-lattice of Jahn-Teller centers in hexaferrite crystal

A novel type of sub-lattice of the Jahn-Teller (JT) centers was arranged in Ti-doped barium hexaferrite BaFe12O19. In the un-doped crystal all iron ions, sitting in five different crystallographic positions, are Fe3+ in the high-spin configuration (S = 5/2) and have a non-degenerate ground state. We show that the electron-donor Ti substitution converts the ions to Fe2+ predominantly in tetrahedral coordination, resulting in doubly-degenerate states subject to the E⊗ e problem of the JT effect. The arranged JT complexes, Fe2+O4, their adiabatic potential energy, non-linear and quantum dynamics, have been studied by means of ultrasound and terahertz-infrared spectroscopies. The JT complexes are sensitive to external stress and applied magnetic field. For that reason, the properties of the doped crystal can be controlled by the amount and state of the JT complexes. © 2020, The Author(s).Deutscher Akademischer Austauschdienst, DAADRussian Foundation for Basic Research, RFBR: 18–02–00332 aDeutscher Akademischer Austauschdienst, DAAD: 91728513Ministry of Education and Science of the Russian Federation, Minobrnauka: 19–53–0401019–72–00055Ministry of Education and Science of the Russian Federation, MinobrnaukaThe authors acknowledge fruitful discussions with A.S. Prokhorov. We acknowledge support of the HLD at HZDR, member of the European Magnetic Field Laboratory (EMFL). At Ural Federal University, the research was supported by the Russian Foundation for Basic Research (18–02–00332 a), UrFU Center of Excellence “Radiation and Nuclear Technologies” (Competitiveness Enhancement Program), the Ministry of Education and Science of the Russian Federation (Program 5–100). In M.N. Miheev Institute of Metal Physics, the research was carried out within the state assignment of the Ministry of Education and Science of the Russian Federation (theme “Electron” No. AAAA-A18–118020190098–5. At South Ural State University, the authors were generally supported by Act 211 Government of the Russian Federation, contract № 02.A03.21.0011. The single crystal growth part was supported by Russian Foundation for Basic Research (19–53–04010). At Moscow Institute of Physics and Technology, the work was supported by the Russian Ministry of Education and Science (Program 5–100) and by the German Academic Exchange Service (DAAD) Michael Lomonosov Programm Linie B, 91728513. Time-domain low temperature spectroscopic experiments were financially supported by the Russian Scientific Foundation (19–72–00055)

Mesenchymal stromal cells of bone marrow and azathioprine in Crohn's disease therapy

Crohn's disease (CD) is a chronic, recurring disease of the gastrointestinal tract of unclear etiology. One of the new approaches to CD therapy is the use of the possibilities of stem cells, in particular, mesenchymal stromal cells (MSCs). Currently, the use of MSC in clinical practice for the treatment of chronic inflammatory and autoimmune diseases is being studied in patients who receive concomitant therapy with other immunomodulatory medications. Aim. To evaluate the effectiveness of MSCs therapy in patients with CD receiving azathioprine (AZA). Materials and methods. The study included 34 patients with inflammatory (luminal) form of CD. The 1st group of patients (n=15) received anti-inflammatory therapy using MSCs culture in combination with AZA. The 2nd group (n=19) received MSCs without AZA. The severity of the attack was assessed in points in accordance with the of Crohn's disease activity index (CDAI). Immunoglobulins (IgA, IgG, IgM), interleukins (IL) 1β, 4, 10, tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), transforming growth factor-1β (TGF-1β), C-reactive protein (CRP), platelets and erythrocyte sedimentation rate (ESR) at 2, 6 and 12 months from the beginning of MSCs therapy. Results. The initial mean CDAI in the 1st group was 337.6±17.1 points, in the 2nd group - 332.7±11.0 points (p=0.3). In both groups of patients there was a significant decrease in CDAI after 2 months. From the beginning of therapy MSCs: in the 1st group to 118.9±12.4 points, in the 2nd - 120.3±14.1 points (p=0.7), after 6 months - 110.3±11.1 and 114.3±11.8 points (p=0.8), respectively. After 12 months CDAI in the 1st group was 99.9±10.8 points, in the 2nd group it was 100.6±12.1 points (p=0.8). The level of IgA, IgG, IgM was significantly lower in the group of patients with a longer history of the disease and long-term ASA. After the introduction of MSC in both groups of patients with BC, there was a tendency for the growth of pro - and anti-inflammatory cytokines, with a significantly lower level of pro-inflammatory cytokines - INF-γ, TNF-α, IL-1β - in the 1st group, indicating potentiation of the immunosuppressive effect of MSCs and AZA, which provides a more pronounced anti-inflammatory effect. Conclusion. Transplantation of MSCs promotes an increase in the serum of patients with CD initially reduced concentration of IG, cytokines and restoring their balance as the onset of clinical remission. The combination with AZA has a more pronounced anti-inflammatory effect

Important problems in the diagnosis and treatment of autoimmune hepatitis (based on the Russian consensus 2017)

The analysis of publications devoted to the Russian Consensus on the Diagnostic and Treatment of Autoimmune Hepatitis (AIH), which was considered at the 43rd annual Scientific Session of the CNIIG From Traditions to Innovation (March 4, 2017) is carried out. The presence of clear algorithms and recommendations for the diagnosis and treatment of AIH significantly help the doctor in real clinical practice, but do not exclude a personified approach to the patient

Surface waves and crustal structure on Mars

We detected surface waves from two meteorite impacts on Mars. By measuring group velocity dispersion along the impact-lander path, we obtained a direct constraint on crustal structure away from the InSight lander. The crust north of the equatorial dichotomy had a shear wave velocity of approximately 3.2 kilometers per second in the 5- to 30-kilometer depth range, with little depth variation. This implies a higher crustal density than inferred beneath the lander, suggesting either compositional differences or reduced porosity in the volcanic areas traversed by the surface waves. The lower velocities and the crustal layering observed beneath the landing site down to a 10-kilometer depth are not a global feature. Structural variations revealed by surface waves hold implications for models of the formation and thickness of the martian crust.D.K., S.C., D.G., J.C., C.D., A. K., S.C.S., N.D., and G.Z. were supported by the ETH+ funding scheme (ETH+02 19-1: “Planet Mars”). Marsquake Service operations at ETH Zürich were supported by ETH Research grant ETH-06 17-02. N.C.S. and V.L. were supported by NASA PSP grant no. 80NSSC18K1628. Q.H. and E.B. are funded by NASA grant 80NSSC18K1680. C.B. and J.L. were supported by NASA InSight PSP grant no. 80NSSC18K1679. S.D.K. was supported by NASA InSight PSP grant no. 80NSSC18K1623. P.L., E.B., M.D., H.S., E.S., M.W., Z.X., T.W., M.P., R.F.G. were supported by CNES and the Agence Nationale de la Recherche (ANR-19-CE31-0008-08 MAGIS) for SEIS operation and SEIS Science analysis. A.H., C.C. and W.T.P. were supported by the UKSA under grant nos. ST/R002096/1, ST/ W002523/1 and ST/V00638X/1. Numerical computations of McMC Approach 2 were performed on the S-CAPAD/DANTE platform (IPGP, France) and using the HPC resources of IDRIS under the allocation A0110413017 made by GENCI. A.H. was supported by the UKSA under grant nos. ST/R002096/1 and ST/W002523/1. F.N. was supported by InSight PSP 80NSSC18K1627. I.J.D. was supported by NASA InSight PSP grant no. 80NSSC20K0971. L.V.P. was funded by NASANNN12AA01C with subcontract JPL-1515835. The research was carried out in part by W.B.B., M.G. and M.P.P. at the Jet Propulsion Laboratory, California Institute of Technology, under a contract with the National Aeronautics and Space Administration (80NM0018D0004)Peer reviewe

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study

Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the optimal drug sequence. Expansion of the arsenal of therapeutic possibilities and the use of new combinations will certainly improve the results of treatment of this category of patients and increase their life expectancy.Aim. We sought to describe treatment patterns of  eribulin  and clinical outcomes of  metastatic HER2-positive breast cancer treated with eribulin  plus trastuzumab combination in  academic institutions and community oncology practices across the Russian Federation.Materials and methods. Patients treated with eribulin anytime between Jan, 2014 and Sep, 2019 with a diagnosis of MBC were identified by 23 providers from Russia. Providers retrospectively reviewed the health records and abstracted selected data points into an electronic case report form for each eligible patient.Results. 100 HER2-positive pts received eribulin in combination with trastuzumab. Median age was 55 (31–80) yrs and ECOG status 0–3. 67% pts had visceral metastases. Eribulin was administered as 1st and 2nd line to 23 (23%) pts, 3rd line to 31 (31%) pts, 4th line and later to 46 (46%). Median number of cycles was 5 (2–27). ORR was 12%, SD – 72%, SD > 6 months – 23%, PD – 16%. Clinical efficacy rate achieved in 35%. Median PFS was 5.07 months (95% CI 4.021–6.119). According to the ER-status the response to eribulin and trastuzumab was different. ORR was 18.8%, SD 72.9% in pts with ER-positive MBC (n = 48) and 5.8% and 71.2% respectively in ER-negative MBC (n = 52). Median PFS was 6.97 months (95% CI 3.924–10.016) in pts with ER-positive MBC and 4.67 months (95% CI 3.841–5.499) in ER-negative MBC (р = 0.3). The combination was well tolerated: dose reductions were required in 12% pts, withdrawal due to toxicity in 4% pts. The most common type of toxicity was hematological with neutropenia Gr III-IV in 14 (14%) pts. Peripheral neuropathy Gr III was observed in 5 (5%) pts. No cardiotoxicity was detected.Conclusions. This is the real-life data of clinical outcomes for patients receiving eribulin plus trastuzumab for HER2-positive MBC throughout the Russian Federation. Our experience with eribulin plus trastuzumab demonstrates that this combination may be a potential effective treatment option for HER-2 positive MBC patients

Search for an invisible Z′Z^\prime in a final state with two muons and missing energy at Belle II

The $L_{\mu}-L_{\tau}$ extension of the standard model predicts the existence of a lepton-flavor-universality-violating $Z^{\prime}$ boson that couples only to the heavier lepton families. We search for such a $Z^\prime$ through its invisible decay in the process $e^+ e^- \to \mu^+ \mu^- Z^{\prime}$. We use a sample of electron-positron collisions at a center-of-mass energy of 10.58GeV collected by the Belle II experiment in 2019-2020, corresponding to an integrated luminosity of 79.7fb$^{-1}$. We find no excess over the expected standard-model background. We set 90$\%$-confidence-level upper limits on the cross section for this process as well as on the coupling of the model, which ranges from $3 \times 10^{-3}$ at low $Z^{\prime}$ masses to 1 at $Z^{\prime}$ masses of 8$GeV/c^{2}$

Measurement of C ⁣PC\!P asymmetries and branching-fraction ratios for B±→DK±B^\pm \to DK^\pm and Dπ±D\pi^\pm with D→KS0K±π∓D\to K^0_{\rm S} K^\pm\pi^\mp using Belle and Belle II data

We measure $C\!P$ asymmetries and branching-fraction ratios for $B^\pm \to DK^\pm$ and $D\pi^\pm$ decays with $D\to K^0_{\rm S} K^\pm\pi^\mp$, where $D$ is a superposition of $D^0$ and $\bar{D}^0$. We use the full data set of the Belle experiment, containing $772\times 10^6~B\bar{B}$ pairs, and data from the Belle~II experiment, containing $387\times 10^6~B\bar{B}$ pairs, both collected in electron-positron collisions at the $\Upsilon(4S)$ resonance. Our results provide model-independent information on the unitarity triangle angle $\phi_3$.Comment: 26 pages, 8 figure

Tests of light-lepton universality in angular asymmetries of B0→D∗−ℓνB^0 \to D^{*-} \ell \nu decays

We present the first comprehensive tests of light-lepton universality in the angular distributions of semileptonic \Bz-meson decays to charged spin-1 charmed mesons. We measure five angular-asymmetry observables as functions of the decay recoil that are sensitive to lepton-universality-violating contributions. We use events where one neutral \B is fully reconstructed in \PUpsilonFourS{} \to\B\overline{B} decays in data corresponding to \lumion integrated luminosity from electron-positron collisions collected with the \belletwo detector. We find no significant deviation from the standard model expectations